Diagnosis of Endocrine Dysfunctions in Covid-19

NCT04587375 | Completed

• 1 other identifier: RECHMPL20_0205
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

As observed with SARS-CoV responsible for SARS 2003, the new coronarovirus SARS-CoV-2 uses the angiotensin converting enzyme type 2 (ACE2) as cellular receptor to infect cells. The renin aldosterone angiostensin system (RAAS) has known effects in the lungs: some receptors are pro-inflammatory, others are anti-inflammatory. Thus the deregulation of the RAAS induced by the SARS-CoV-2 could explain the inflammatory response of Covid-19 infection and be a modulator of the severity of its course. Furthermore, the SARS 2003 experience suggests that there may be others endocrine involvment, particularly an failure on the hypothalamus-pituitary and adrenal axis. Indeeed, cases of hypocorticism and hypothyroidism of central origin were described. Altogether, the endocrine system might play a role both in the pathophysiology of Covid-19 infection and in the activity and severity of the disease. In this study, the investigators proposed to explore endocrine functions on biological samples in a series of patients admitted for Covid-19 in our clinic.

Conditions

Covid 19

Keywords

Covid-19; Renin Angiotensin Aldosterone System; Hormon disorders

Outcome Measures

Primary Outcomes (2)

• Plasma aldosterone levels

  Plasma aldosterone levels

  1 day (at inclusion)

• Plasma renin levels

  Plasma renin levels

  1 day (at inclusion)

Secondary Outcomes (20)

• covid-19 infection severity

  1 day (at inclusion)

• Maximum severity of Covid-19 infection

  1 day (at inclusion)

• Plasma aldosterone level

  1 day (at the end of hospitalization)

• Plasma ACTH level

  1 day (at the end of hospitalization)

• Plasma cortisol level

  1 day (at inclusion)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with Covid-19 diagnosis hospitalized in Montpellier University hospital

You may qualify if:

• \- Patients with Covid-19 diagnosis and hospitalized in our clinic

You may not qualify if:

• \- Minor patient

Sponsors & Collaborators

• University Hospital, Montpellier: lead

Study Sites (1)

Uhmontpellier

Montpellier, 34295, France

Location

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Philippe GUILPAIN, MD, PhD

  University Hospital, Montpellier

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 18, 2020
• First Posted: October 14, 2020
• Study Start: March 1, 2020
• Primary Completion: May 1, 2020
• Study Completion: May 30, 2020
• Last Updated: October 14, 2020

Record last verified: 2020-09

Locations

FR (1)